Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2 Recruiting
314 enrolled
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Phase 2/3 Recruiting
992 enrolled
EXACT
Phase 2 Recruiting
70 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Phase 1 Recruiting
14 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Phase 1/2 Recruiting
234 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Phase 1 Recruiting
33 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Phase 2 Recruiting
120 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
Phase 1/2 Recruiting
60 enrolled
SAMURAI
Phase 2 Recruiting
240 enrolled
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Phase 2 Recruiting
50 enrolled
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Phase 2 Recruiting
111 enrolled
International Multicentric Study ARON-1
Recruiting
1,220 enrolled
PSI-Immune
Phase 2 Recruiting
480 enrolled
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2 Recruiting
126 enrolled
CANIQOL
Phase 4 Recruiting
83 enrolled
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Phase 1/2 Recruiting
100 enrolled
CABOLD
Phase 4 Recruiting
50 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Phase 1/2 Recruiting
55 enrolled
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Phase 2 Recruiting
54 enrolled
Cyto-KIK
Phase 2 Recruiting
48 enrolled
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
Phase 2 Recruiting
23 enrolled
CARE1
Phase 3 Recruiting
1,250 enrolled
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Phase 1 Recruiting
28 enrolled
AxIn
Phase 2 Recruiting
118 enrolled
CRIMI
Phase 1/2 Recruiting
50 enrolled